Toshiba Vantage Titan 1.5T

Toshiba Vantage Titan 1.5T – General Information

The Toshiba Vantage Titan 1.5T was designed to satisfy the demands of a challenging clinical environment. It addresses the needs of patients, clinicians, and technologists in a single, scalable and powerful MRI platform that offers a great performance.

They increased the patient-friendliness with a soft lighting in the gantry, a wide aperture, and a short open-bore design. Moreover, the Toshiba Vantage Titan is very quiet, due to an active hardware solution for noise reduction, the Pianissimo™ technology that reduces acoustic noise by up to 90%. These features create a safe and enjoyable scanning environment, which results in faster exams as patients are relaxed and compliant. Hereby the Toshiba Vantage Titan 1.5T increases throughput and productivity.

Clinicians find great value in the industry’s leading high-resolution, non-contrast technology on the Toshiba Vantage Titan 1.5T. Four generations of non-contrast techniques capture the highest quality MRI angiography images and hereby eliminate the need for laboratory tests.

Furthermore, the Toshiba Vantage Titan 1.5T provides dynamic RF solutions tailored to any facility. Therefore, it makes it easy to satisfy your current scanning needs and protect your investment in the future. The system carries a wide range of advanced features. As mentioned, it is the first MRI scanner with an active hardware solution for reducing acoustic noise. Additionally, it is the system with the widest selection of non-contrast MRA techniques available.

Moreover, the system has a reduced power consumption – great both for the environment and keeping down the operating costs. M-Power software platform enables clinicians to easily learn how to use the full functionality of the machine. You can start a scan in three quick steps and this reduces time and increase the patient volume. Furthermore, it gives easy access to the advanced post-processing of the Toshiba Vantage Titan 1.5T.

Details

Category
Posted September 9, 2019